We believe in the importance of investing for the long term, diversifying your portfolio, and using trailing stops to limit your downside and lock in your gains.
We also agree that we live in an incredible country.
American ingenuity, technology and capital markets have created dramatic improvements in communications, transportation, manufacturing, computing, retail, food production, construction, healthcare, finance, pharmaceuticals, robotics, sensors, artificial intelligence, genetics and dozens of other industries.
We can't even imagine all the fantastic innovations that lie ahead of us - especially in terms of healthcare.
It's easy to overlook the triumph of science over disease in the past 100 years.
During this period, polio, smallpox, typhoid, tetanus, whooping cough, measles and diphtheria have all been controlled or eradicated. These victories helped double the human life span in the 20th century.
In recent years, medical research has made significant inroads in the treatment of the nation's two biggest killers: heart disease and cancer.
The National Cancer Institute reports that the risk of dying from cancer declined 22% between 1991 and 2011. Heart disease and stroke deaths have also fallen dramatically.
Our longer, healthier lives have also created an economic benefit. In inflation-adjusted terms, Americans' per capita output is eight times what it was in the 19th century. Much of this is directly linked to progress against disease.
Yet hundreds of diseases still cry out for effective cures or treatment.
I've been arguing for years that the best way to play American innovation is with a careful selection of small cap and midcap biotechs.
I learned early on that Marc has a knack for identifying such companies. (In 2007, BioMarin's market cap was around $2.5 billion. Today, it's $22 billion.)
Last year, Marc partnered with former Speaker of the House Newt Gingrich for The 2019 American Health & Wealth Summit. During the summit, they discussed the investing and economic opportunities within the gene therapy subsector of biotech. Since then, gene therapy companies (as measured by a JPMorgan Genetic Therapies fund) have produced a total return of 37.48%. Meanwhile, the S&P 500 has returned a paltry 4.41% over the same period. Now Marc is researching a catalyst that Wall Street has been using for nearly three decades to successfully play the biotech sector. And it has nothing to do with clinical trials or earnings reports. Using this catalyst, Marc believes investors can double their money 12 times over 12 months. Based on his track record, I know I'll be watching his latest presentation closely. Click here to see Marc's latest biotech research. Good investing, Alex
| 
No comments:
Post a Comment